Emerging adenosine receptor agonists

Bibliography

• DRURY AN, SZENT-GYORGYI A: The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J. Physiol. (Lond.) (1929) 68:213-237.
   Google Scholar
• SATTIN A, RALL TW: The effect of adenosine and adenine nucleotides on the cyclic adenosine 3′,5′-phosphate content of guinea pig cerebral cortex slices. Mol. Pharmacol. (1970) 6:13-23.
   PubMed Web of Science ®Google Scholar
• DALY JW: Cyclic Nucleotides in the Nervous System. Plenum Press, New York (1977).
   Google Scholar
• FREDHOLM BB: Are methylxanthine effects due to antagonism of endogenous adenosine? Trends Pharmacol. Sci. (1980) 1:129-132.
   Web of Science ®Google Scholar
• VAN CALKER D, MULLER M, HAMPRECHT B: Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. (1979) 33:999-1005.
   PubMed Web of Science ®Google Scholar
• LONDOS C, COOPER DM, WOLFF J: Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci. USA (1980) 77:2551-2554.
   PubMed Web of Science ®Google Scholar
• SCHULTE G, FREDHOLM BB: Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal (2003) 15:813-827.
   PubMed Web of Science ®Google Scholar
• DIXON AK, GUBITZ AK, SIRINATHSINGHJI DJ, RICHARDSON PJ, FREEMAN TC: Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmacol. (1996) 118:1461-1468.
   PubMed Web of Science ®Google Scholar
• FREDHOLM BB, IJZERMAN AP, JACOBSON KA, KLOTZ KN, LINDEN J: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. (2001) 53:527-552.
   PubMed Web of Science ®Google Scholar
• PASCUAL O, CASPER KB, KUBERA C et al.: Astrocytic purinergic signaling coordinates synaptic networks. Science (2005) 310:113-116.
   PubMed Web of Science ®Google Scholar
• CHRISTOFI FL, ZHANG H, YU JG et al.: Differential gene expression of adenosine A1, A2a, A2b, and A3 receptors in the human enteric nervous system. J. Comp. Neurol. (2001) 439:46-64.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA, GAO ZG: Adenosine receptors as therapeutic targets. Nat. Rev. Drug Disc. (2006) 5:247-264.
   PubMed Web of Science ®Google Scholar
• CHEN Y, CORRIDEN R, INOUE Y et al.: ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science (2006) 314:1792-1795.
   PubMed Web of Science ®Google Scholar
• LINDEN J: Cell biology. Purinergic chemotaxis. Science (2006) 314:1689-1690.
   PubMed Web of Science ®Google Scholar
• SALVATORE CA, JACOBSON MA, TAYLOR HE, LINDEN J, JOHNSON RG: Molecular cloning and characterization of the human A3 adenosine receptor. Proc. Natl. Acad. Sci. USA (1993) 90:10365-10369.
   PubMed Web of Science ®Google Scholar
• ZHOU QY, LI C, OLAH ME, JOHNSON RA, STILES GL, CIVELLI O: Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc. Natl. Acad. Sci. USA (1992) 89:7432-7436.
   PubMed Web of Science ®Google Scholar
• JOHANSSON B, HALLDNER L, DUNWIDDIE TV et al.: Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc. Natl. Acad. Sci. USA (2001) 98:9407-9412.
   PubMed Web of Science ®Google Scholar
• LEDENT C, VAUGEOIS JM, SCHIFFMANN S et al.: Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature (1997) 388:674-678.
   PubMed Web of Science ®Google Scholar
• YANG D, MCCRANN DJ, NGUYEN H et al.: The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J. Clin. Invest. (2006) 116:1913-1923.
   PubMed Web of Science ®Google Scholar
• SALVATORE CA, TILLEY SL, LATOUR AM, FLETCHER DS, KOLLER BH, JACOBSON MA: Disruption of the A3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. (2000) 275:4429-4434.
   PubMed Web of Science ®Google Scholar
• FREDHOLM BB, CHEN JF, MASINO SA, VAUGEOIS JM: Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Ann. Rev. Pharmacol. Toxicol. (2005) 45:385-412.
   PubMed Web of Science ®Google Scholar
• HUANG ZL, QU WM, EGUCHI N et al.: Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat. Neurosci. (2005) 8:858-859.
   PubMed Web of Science ®Google Scholar
• SUN CX, ZHONG H, MOHSENIN A et al.: Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J. Clin. Invest. (2006) 116:2173-2182.
   PubMed Web of Science ®Google Scholar
• LINDEN J: New insights into the regulation of inflammation by adenosine. J. Clin. Invest. (2006) 116:1835-1837.
   PubMed Web of Science ®Google Scholar
• FEDOROVA IM, JACOBSON MA, BASILE A, JACOBSON KA: Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. Cell Mol. Neurobiol. (2003) 23:431-447.
   PubMed Web of Science ®Google Scholar
• YAN L, BURBIEL JC MAASS A, MÜLLER CE: Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin. Emerging Drugs (2003) 8:537-576.
   PubMedGoogle Scholar
• GOLDSTEIN RN, STAMBLER BS: New antiarrhythmic drugs for prevention of atrial fibrillation. Prog. Cardiovasc. Dis. (2005) 48:193-208.
   PubMed Web of Science ®Google Scholar
• OREJARENA LA, VIDAILLET H JR, DESTEFANO F et al.: Paroxysmal supraventricular tachycardia in the general population. J. Am. Coll. Cardiol. (1998) 31:150-157.
   PubMed Web of Science ®Google Scholar
• BLOMSTROM-LUNDQVIST C, SCHEINMAN MM, ALIOT EM et al.: American College of Cardiology; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines. Writing Committee to Develop Guidelines for the Management of Patients with Supraventricular Arrhythmias. Circulation (2003) 108:1871-1909.
   PubMed Web of Science ®Google Scholar
• DHALLA AK, SHRYOCK JC, SHREENIWAS R, BELARDINELLI L: Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr. Top. Med. Chem. (2003) 3:369-385.
   PubMed Web of Science ®Google Scholar
• HEBBAR AK, HUESTON WJ: Management of common arrhythmias: Part I. Supraventricular arrhythmias. Am. Fam. Physician (2002) 65:2479-2486.
   PubMed Web of Science ®Google Scholar
• STRICKBERGER SA, MAN KC, DAOUD EG et al.: Adenosine-induced atrial arrhythmia: a prospective analysis. Ann. Intern. Med. (1997) 127:417-422.
   PubMed Web of Science ®Google Scholar
• PETERMAN C, SANOSKI CA: Tecadenoson: a novel, selective A1 adenosine receptor agonist. Cardiol. Rev. (2005) 13:315-321.
   PubMedGoogle Scholar
• WALLACE MS: Emerging drugs for neuropathic pain. Expert Opin. Emerging Drugs (2001) 6:249-259.
   PubMedGoogle Scholar
• COLLINS SD, CHESSELL IP: Emerging therapies for neuropathic pain. Expert Opin. Emerging Drugs (2005) 10:95-108.
   PubMedGoogle Scholar
• GILRON I, CODERRE TJ: Emerging drugs in neuropathic pain. Expert Opin. Emerging Drugs (2007) 12:113-126.
   PubMed Web of Science ®Google Scholar
• HENDEL RC, JAMIL T, GLOVER DK: Pharmacologic stress testing: new methods and new agents. J. Nucl. Cardiol. (2003) 10:197-204.
   PubMed Web of Science ®Google Scholar
• CERQUEIRA MD: Advances in pharmacologic agents in imaging: new A2A receptor agonists. Curr. Cardiol. Rep. (2006) 8:119-122.
   PubMedGoogle Scholar
• SITKOVSKY MV, LUKASHEV D, APASOV S et al.: Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Ann. Rev. Immunol. (2004) 22:657-682.
   PubMed Web of Science ®Google Scholar
• LINDEN J: Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Ann. Rev. Pharmacol. Toxicol. (2001) 41:775-787.
   PubMed Web of Science ®Google Scholar
• SMOLEN JS, ALETAHA D: Challenges of predicting treatment response in patients with rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. (2005) 1:62-63.
   PubMedGoogle Scholar
• SCHOEN RE: The case for population-based screening for colorectal cancer. Nat. Rev. Cancer (2002) 2:65-70.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA, JI X, LI AH et al.: Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J. Med. Chem. (2000) 43:2196-2203.
   PubMed Web of Science ®Google Scholar
• JEONG LS, JIN DZ, KIM HO et al.: N6-substituted D-4′-thioadenosine-5′-methyluronamides: potent and selective agonists at the human A3 adenosine receptor. J. Med. Chem. (2003) 46:3775-3777.
   PubMed Web of Science ®Google Scholar
• GAO ZG, BLAUSTEIN JB, GROSS AS, MELMAN N, JACOBSON KA: N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors. Biochem. Pharmacol. (2003) 65:1675-1684.
   PubMed Web of Science ®Google Scholar
• KLOTZ KN, HESSLING J, HEGLER J et al.: Comparative pharmacology of human adenosine receptor subtypes – characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch. Pharmacol. (1998) 357:1-9.
   PubMed Web of Science ®Google Scholar
• BARALDI PG, PRETI D, TABRAZI MA et al.: Synthesis and biological evaluation of novel 1-deoxy-1-[6-[((hetero)arylcarbonyl)hydrazino]- 9H-purin-9-yl]-N-ethyl-β-D-ribofuranuronamide derivatives as useful templates for the development of A2B adenosine receptor agonists. J. Med. Chem. (2007) 50:374-380.
   PubMed Web of Science ®Google Scholar
• KIM HO, JI XD, SIDDIQI SM et al.: 2-Substitution of N6-benzyladenosine-5′-uronamides enhances selectivity for A3 adenosine receptors. J. Med. Chem. (1994) 37:3614-3621.
   PubMed Web of Science ®Google Scholar
• JIN X, SHEPHERD RK, DULING BR, LINDEN J: Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J. Clin. Invest. (1997) 100:2849-2857.
   PubMed Web of Science ®Google Scholar
• BEUKERS MW, CHANG LC, VON FRIJTAG DRABBE KUNZEL JK et al.: New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. J. Med. Chem. (2004) 47:3707-3709.
   PubMed Web of Science ®Google Scholar
• KRAHN T, ALBRECT B, ROSENTRETER U, COHEN MV, SOLENKOVA, DOWNEY JM: Adenosine A2B receptor agonist mimics postconditioning: characterization of a selective adenosine A2B agonist in a rabbit infarct model. Purinergic Signal. (2006) 2:105-106.
   Google Scholar
• ECKLE T, KRAHN T, GRENZ A et al.: Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation (2007) 115:1581-1590.
   PubMed Web of Science ®Google Scholar
• VERYARD C: Developments in cardiovascular-related therapies. IDrugs (2007) 10:14-16.
   PubMed Web of Science ®Google Scholar
• CHANG LC, VON FRIJTAG DRABBE KUNZEL JK, MULDER-KRIEGER T et al.: A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. J. Med. Chem. (2005) 48:2045-2053.
   PubMed Web of Science ®Google Scholar
• SCHUMACHER B, SCHOLLE S, HÖLZL J, KHUDEIR N, HESS S, MÜLLER CE: Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A1 adenosine receptors. J. Nat. Prod. (2002) 65:1479-1485.
   PubMed Web of Science ®Google Scholar
• KEHRAUS S, GORZALKA S, HALLMEN C et al.: Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique adenosine derivative. J. Med. Chem. (2004) 47:2243-2255.
   PubMed Web of Science ®Google Scholar
• GAO ZG, KIM SK, IJZERMAN AP, JACOBSON KA: Allosteric modulation of the adenosine family of receptors. Mini Rev. Med. Chem. (2005) 5:545-553, 2005.
   PubMed Web of Science ®Google Scholar
• GÖBLYÖS A, GAO ZG, BRUSSEE J et al.: Structure–activity relationships of 1H-imidazo-[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor. J. Med. Chem. (2006) 49:3354-3361.
   PubMed Web of Science ®Google Scholar
• WU L, BELARDINELLI L, ZABLOCKI JA, PALLE V, SHRYOCK JC: A partial agonist of the A1-adenosine receptor selectively slows AV conduction in guinea pig hearts. Am. J. Physiol. Heart Circ. Physiol. (2001) 280:H334-H343.
   PubMed Web of Science ®Google Scholar
• ZABLOCKI JA, WU L, SHRYOCK J, BELARDINELLI L: Partial A1 adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF). Curr. Top. Med. Chem. (2004) 4:839-854.
   PubMed Web of Science ®Google Scholar
• WU WP, HAO JX, HALLDNER L et al.: Increased nociceptive response in mice lacking the adenosine A1 receptor. Pain (2005) 113:395-404.
   PubMed Web of Science ®Google Scholar
• CHILDERS SR, LI X, XIAO R, EISENACH JC: Allosteric modulation of adenosine A1 receptor coupling to G-proteins in brain. J. Neurochem. (2005) 93:715-723.
   PubMed Web of Science ®Google Scholar
• EGGEBRECHT H, GOSSL M: Regadenoson (CV Therapeutics/Astellas). Curr. Opin. Investig. Drugs (2006) 7:264-271.
   PubMed Web of Science ®Google Scholar
• SULLIVAN GW: Adenosine A2A receptor agonists as anti-inflammatory agents. Curr. Opin. Investig. Drugs (2003) 4:1313-1319.
   PubMedGoogle Scholar
• LAPPAS CM, SULLIVAN GW, LINDEN J: Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin. Investig. Drugs (2005) 14:797-806.
   PubMed Web of Science ®Google Scholar
• LAPPAS CM, DAY YJ, MARSHALL MA, ENGELHARD VH, LINDEN J: Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J. Exp. Med. (2006) 203:2639-2648.
   PubMed Web of Science ®Google Scholar
• AKKARI R, BURBIEL JC, HOCKEMEYER J, MULLER CE: Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr. Top. Med. Chem. (2006) 6:1375-1399.
   PubMed Web of Science ®Google Scholar
• CRISTALLI G, CACCIARI B, DAL BEN D et al.: Highlights on the Development of A2A adenosine receptor agonists and antagonists. Chem. Med. Chem. (2007) 2:260-281.
   Google Scholar
• HASKO G, PACHER P, DEITCH EA, VIZI ES: Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol. Ther. (2007) 113:264-275.
   PubMed Web of Science ®Google Scholar
• NEMETH ZH, LUTZ CS, CSOKA B et al.: Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism. J. Immunol. (2005) 175:8260-8270.
   PubMed Web of Science ®Google Scholar
• KRECKLER LM, WAN TC, GE ZD, AUCHAMPACH JA: Adenosine inhibits TNF-α release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J. Pharmacol. Exp. Ther. (2006) 317:172-180.
   PubMed Web of Science ®Google Scholar
• MONTESINOS MC, DESAI A, DELANO D et al.: Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. (2003) 48:240-247.
   PubMed Web of Science ®Google Scholar
• SZABO C, SCOTT GS, VIRAG L et al.: Suppression of macrophage inflammatory protein (MIP)-1α production and collagen-induced arthritis by adenosine receptor agonists. Br. J. Pharmacol. (1998) 125:379-387.
   PubMed Web of Science ®Google Scholar
• MADI L, COHEN S, OCHAYIN A, BAR-YEHUDA S, BARER F, FISHMAN P: Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of NF-κB in mediating receptor level. J. Rheumatol. (2007) 34:20-26.
   PubMed Web of Science ®Google Scholar
• BAHARAV E, BAR-YEHUDA S, MADI L et al.: Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J. Rheumatol. (2005) 32:469-476.
   PubMed Web of Science ®Google Scholar
• PETROVA N, EDMONDS M: Emerging drugs for diabetic foot ulcers. Expert Opin. Emerging Drugs (2006) 11:709-724.
   PubMedGoogle Scholar
• LIPSKY PE: A modest proposal. Nat. Clin. Pract. Rheumatol. (2006) 2:343.
   PubMedGoogle Scholar
• KOHNO Y, SEI Y, KOSHIBA M, KIM HO, JACOBSON KA: Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A3 receptor agonists. Biochem. Biophys. Res. Commun. (1996) 219:904-910.
   PubMed Web of Science ®Google Scholar
• GAO Z, LI BS, DAY YJ, LINDEN J: A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol. Pharmacol. (2001) 59:76-82.
   PubMed Web of Science ®Google Scholar
• LU J, PIERRON A, RAVID K: An adenosine analogue, IB-MECA, down-regulates estrogen receptor α and suppresses human breast cancer cell proliferation. Cancer Res. (2003) 63:6413-6423.
   PubMed Web of Science ®Google Scholar
• KIM SG, RAVI G, HOFFMANN C et al.: p53-independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA. Biochem. Pharmacol. (2002) 63:871-880.
   PubMed Web of Science ®Google Scholar
• LEE EJ, MIN HY, CHUNG HJ et al.: A novel adenosine analog, thio-Cl-IB-MECA, induces G0/G1 cell cycle arrest and apoptosis in human promyelocytic leukemia HL-60 cells. Biochem. Pharmacol. (2005) 70:918-924.
   PubMed Web of Science ®Google Scholar
• MERIGHI S, MIRANDOLA P, VARANI K et al.: A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol. Ther. (2003) 100:31-48.
   PubMed Web of Science ®Google Scholar
• MERIGHI S, MIRANDOLA P, MILANI D et al.: Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J. Invest. Dermatol. (2002) 119:923-933.
   PubMed Web of Science ®Google Scholar
• MERIGHI S, BENINI A, MIRANDOLA P et al.: A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase (PI3K)/AKT-dependent inhibition of the extracellular signal-regulated kinase (ERK)1/2 phosphorylation in A375 human melanoma cells. J. Biol. Chem. (2005) 280:19516-19526.
   PubMed Web of Science ®Google Scholar
• GESSI S, MERIGHI S, VARANI K et al.: Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A3 adenosine subtype. J. Cell Physiol. (2007) 211:826-836.
   PubMed Web of Science ®Google Scholar
• GESSI S, CATTABRIGA E, AVITABILE A et al.: Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin. Cancer Res. (2004) 10:5895-5901.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, BAR-YEHUDA S, VAGMAN L: Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. Cancer Res. (1998) 58:3181-3187.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, BAR-YEHUDA S, OHANA G et al.: Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor. Eur. J. Cancer (2000) 36:1452-1458.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, MADI L, BAR-YEHUDA S, BARER F, DEL VALLE L, KHALILI K: Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene (2002) 21:4060-4064.
   PubMed Web of Science ®Google Scholar
• OHANA G, BAR-YEHUDA S, ARICH A et al.: Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. Br. J. Cancer (2003) 89:1552-1558.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, BAR-YEHUDA S, OHANA G et al.: An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 β and NF-κB. Oncogene (2004) 23:2465-2471.
   PubMed Web of Science ®Google Scholar
• BAR-YEHUDA S, MADI L, SILBERMAN D, GERY S, SHKAPENUK M, FISHMAN P: CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia (2005) 7:85-90.
   PubMed Web of Science ®Google Scholar
• BAR-YEHUDA S, MADI L, BARAK D et al.: Agonists to the A3 adenosine receptor induce G-CSF production via NF-κB activation: a new class of myeloprotective agents. Exp. Hematol. (2002) 30:1390-1398.
   PubMed Web of Science ®Google Scholar
• MADI L, OCHAION A, RATH-WOLFSON L et al.: The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin. Cancer Res. (2004) 10:4472-4479.
   PubMed Web of Science ®Google Scholar
• ELMENHORST D, MEYER PT, WINZ OH et al.: Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study. J. Neurosci. (2007) 27:2410-2415.
   PubMed Web of Science ®Google Scholar
• BAR-YEHUDA S, OCHAION A, JACOBSON KA et al.: CF502 targets the A3 adenosine receptor to induce anti-inflammatory effect via down-regulation of the NF-κB signaling pathway. Abstract for the 2007 ACR Meeting.
   Google Scholar
• TCHILIBON S, JOSHI BV, KIM SK et al.: (N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J. Med. Chem. (2005) 48:1745-1758.
   PubMed Web of Science ®Google Scholar